Research
Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital
Published

Should immunologic strategies be incorporated into frontline ALL therapy?

Research output: Contribution to journalReviewResearchpeer-review

  1. Autologous transplantation and management of younger patients with mantle cell lymphoma

    Research output: Contribution to journalJournal articleResearchpeer-review

  1. Polygenic risk score-analysis of thromboembolism in patients with acute lymphoblastic leukemia

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Prophylaxis of thromboembolism during therapy with asparaginase in adults with acute lymphoblastic leukaemia (Review)

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Management of Asparaginase Toxicity in AYAs with ALL

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. Optimal approach to the treatment of young adults with acute lymphoblastic leukemia in 2020

    Research output: Contribution to journalJournal articleResearchpeer-review

View graph of relations

Survival rates in adult patients with acute lymphoblastic leukemia (ALL) have markedly improved during the past decade. The one-size-fits-all-ages approach has been replaced with adaptation of pediatric-inspired treatment protocols for younger adults. Yet different treatment strategies for older patients are needed due to chemotherapy-related toxicities. A new era of immunotherapy has arrived, offering opportunities for targeted treatments for ALL subtypes. While CD20 targeting with rituximab has been demonstrated to improve survival when combined with chemotherapy, it has little activity as a single agent in ALL. In contrast, antibody targeting of CD19 and CD22 with blinatumomab and inotuzumab ozogamicin, respectively, has had remarkable single-agent activity in the relapsed setting. Studies are now underway to test these agents in combination with chemotherapy in the frontline setting. The goal of these studies is to improve event-free survival and overall survival by using these approaches in the frontline to eradicate minimal residual disease and, particularly in older adults with ALL, to reduce treatment-related toxicity by limiting the exposure to traditional multi-agent chemotherapy with its attendant toxicities. This review focuses on new immunotherapeutic treatment options and strategies for frontline treatment, including a brief discussion of the use of true immunotherapy, chimeric antigen receptor T-cells, for relapsed B-cell ALL, the potential for targeting CD38 in T-cell ALL, and how these approaches are facilitating the next steps to improve survival for adult patients with ALL.

Original languageEnglish
JournalBest Practice and Research in Clinical Haematology
Volume31
Issue number4
Pages (from-to)367-372
Number of pages6
ISSN1521-6926
DOIs
Publication statusPublished - Dec 2018

    Research areas

  • Antibodies, Bispecific/therapeutic use, Antibodies, Monoclonal, Humanized/therapeutic use, Antigens, CD/immunology, Disease-Free Survival, Humans, Immunotherapy, Inotuzumab Ozogamicin, Neoplasm Proteins/immunology, Precursor Cell Lymphoblastic Leukemia-Lymphoma/immunology, Rituximab/therapeutic use

ID: 59383332